Related Experiment Videos
Extrapulmonary small cell carcinoma: multimodality treatment results.
Meric Sengoz1, Ufuk Abacioglu, Taflan Salepci
1Department of Radiation Oncology, Marmara University Hospital, Istanbul, Turkey. msengoz@marmara.edu.tr
Tumori
|August 12, 2003
Summary
Extrapulmonary small cell carcinoma (ESCC) treatment outcomes are similar to small-cell lung cancer. The extent of disease is a key factor influencing survival in ESCC patients.
Area of Science:
- Oncology
- Medical Research
Background:
- Extrapulmonary small cell carcinoma (ESCC) is a rare malignancy.
- ESCC shares pathological similarities with small-cell lung cancer (SCLC).
Purpose of the Study:
- To evaluate the outcomes of multimodality treatment for ESCC.
- To identify prognostic factors in patients with ESCC.
Main Methods:
- Retrospective study of 16 consecutive ESCC patients.
- Treatment included surgery, radiotherapy, and chemotherapy (predominantly platinum-based).
- Disease extent (limited vs. extensive) was assessed.
Main Results:
- Overall 2-year and 5-year survival rates were 41% and 11%, respectively.
- Median survival was 14 months.
- Limited disease (median 25 months) had significantly better survival than extensive disease (median 12 months).
Conclusions:
- Treatment outcomes for ESCC appear comparable to SCLC.
- Disease extent is a significant prognostic factor for survival in ESCC.